Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer by Brugger Wolfram, Triller Nadja, Blasinska-Morawiec Maria, Curescu Stefan, Sakalauskas Raimundas, Manikhas Georgy Moiseevich, Mazieres Julien, Whittom Renaud, Ward Carol, Mayne Karen, Trunzer Kerstin, Cappuzzo Federico in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011).

[PMID: 21969500] PubMed


Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.